Skip to main content

Vaso Corporation (VASO)

New York Stock Exchange Healthcare Medical - Healthcare Information ServicesView data quality →
59.0Fair

ValueMarkers Composite Index

Top 76%#10,827 of 44,707
Undervalued

71% below intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.92
Low Risk
Altman
1.14
Distress
DCF Value
$1
Undervalued
ROIC
-4.0%
Low
P/E
18.4
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Vaso Corporation (VASO) — VMCI valuation read

The headline on Vaso Corporation (VASO) is a 59/100 VMCI score, set against a Healthcare sector median of 50. That 9-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

VASO insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** VASO trades at 25.0x earnings, 39% above the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 1.0x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on VASO.

VASO fell 1.6% over the trailing 7 days, with a -4.8% read on a 30-day basis.

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

CEO: Jun Ma298 employeesUSwww.vasocorporation.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in VASO’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.